Thomas Lingelbach, Valneva CEO

Val­neva's Covid-19 vac­cine con­tract with Eu­rope col­laps­es to just a frac­tion of the orig­i­nal deal

The Eu­ro­pean Com­mis­sion on Wednes­day an­nounced that it would on­ly pur­chase 1.25 mil­lion dos­es of Val­ne­va’s new­ly au­tho­rized Covid-19 vac­cine, af­ter orig­i­nal­ly pur­chas­ing 60 mil­lion dos­es.

The EC first sent a no­tice of in­tent to ter­mi­nate the pur­chase agree­ment back in May, as the reg­u­la­to­ry re­view of Val­ne­va’s vac­cine stalled. In late June, the Eu­ro­pean Med­i­cines Agency rec­om­mend­ed Val­ne­va’s shot for the pri­ma­ry vac­ci­na­tion of adults, but the com­pa­ny warned that its sup­ply deal might be dead in the wa­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.